<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Sorafenib</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Sorafenib">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Sorafenib</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Sorafenib</b> (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as <b>Nexavar</b>),<span class="mw-ref" id="cite_ref-1"><a href="#cite_note-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.</p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Sorafenib</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Sorafenib2DACS.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Sorafenib2DACS.svg.png" data-file-width="702" data-file-height="307" data-file-type="drawing" height="131" width="300"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Sorafenib_3D_3gcs.png" tppabs="https://ptable.com/wiki/compounds/I/m/Sorafenib_3D_3gcs.png" data-file-width="2700" data-file-height="960" data-file-type="bitmap" height="89" width="250"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Nexavar</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>Nexavar<br>Sorafenib tosylate</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/nexavar.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/nexavar.html'" tppabs="https://www.drugs.com/monograph/nexavar.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a607051.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a607051.html'" tppabs="https://medlineplus.gov/druginfo/meds/a607051.html" class="external text external">a607051</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Sorafenib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Sorafenib'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Sorafenib" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Sorafenib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Sorafenib'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Sorafenib" class="external text external">Sorafenib</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Sorafenib&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Sorafenib&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Sorafenib&SearchType=BasicSearch" class="external text external">Sorafenib</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>D<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>D (Evidence of risk)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L01XE05<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L01XE05  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L01XE05'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L01XE05" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">CA</abbr></small>:<span> </span> ℞-only<span> </span></li>
<li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>38–49%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>99.5%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Hepatic oxidation and glucuronidation (CYP3A4 &amp; UGT1A9-mediated)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>25–48 hours</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Faeces (77%) and urine (19%)</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]<br>phenoxy]-<i>N</i>-methyl-pyridine-2-carboxamide</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=284461-73-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=284461-73-0'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=284461-73-0" class="external text external">284461-73-0</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/216239  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/216239'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/216239" class="external text external">216239</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5711  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5711'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5711" class="external text external">5711</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00398  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00398'" tppabs="https://www.drugbank.ca/drugs/DB00398" class="external text external">DB00398</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.187440.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.187440.html'" tppabs="http://www.chemspider.com/Chemical-Structure.187440.html" class="external text external">187440</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=9ZOQ3TZI87  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=9ZOQ3TZI87'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=9ZOQ3TZI87" class="external text external">9ZOQ3TZI87</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D08524  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D08524'" tppabs="https://www.kegg.jp/entry/D08524" class="external text external">D08524</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50924  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50924'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50924" class="external text external">CHEBI:50924</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1336  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1336'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1336" class="external text external">ChEMBL1336</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PDB ligand</th><td><div class="plainlist"><ul><li>BAX (<span><a href="javascript:if(confirm('https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=BAX  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=BAX'" tppabs="https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=BAX" class="external text external">PDBe</a></span>, <span><a href="javascript:if(confirm('http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=BAX&polymericType=Any  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=BAX&polymericType=Any'" tppabs="http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&chemCompId=BAX&polymericType=Any" class="external text external">RCSB<span>&nbsp;</span>PDB</a></span>)</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID7041128  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID7041128'" tppabs="https://comptox.epa.gov/dashboard/DTXSID7041128" class="external text external">DTXSID7041128</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.110.083  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.110.083'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.110.083" class="external text external">100.110.083</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>21</sub><span>H</span><sub>16</sub><span>Cl</span><span>F</span><sub>3</sub><span>N</span><sub>4</sub><span>O</span><sub>3</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">464.83</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=CNC%28%3DO%29c1cc%28ccn1%29Oc2ccc%28cc2%29NC%28%3DO%29Nc3ccc%28c%28c3%29C%28F%29%28F%29F%29Cl  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=CNC%28%3DO%29c1cc%28ccn1%29Oc2ccc%28cc2%29NC%28%3DO%29Nc3ccc%28c%28c3%29C%28F%29%28F%29F%29Cl'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=CNC%28%3DO%29c1cc%28ccn1%29Oc2ccc%28cc2%29NC%28%3DO%29Nc3ccc%28c%28c3%29C%28F%29%28F%29F%29Cl" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:MLDQJTXFUGDVEO-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=464405524&page2=Sorafenib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=464405524&page2=Sorafenib'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=464405524&page2=Sorafenib" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>Sorafenib is a protein kinase inhibitor with activity against many protein kinases, including VEGFR, PDGFR and RAF kinases.<span class="mw-ref" id="cite_ref-pmid18852116_2-0"><a href="#cite_note-pmid18852116-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Keeting2009_3-0"><a href="#cite_note-Keeting2009-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Of the RAF kinases, Sorafenib is more selective for c-Raf than B-RAF.<span class="mw-ref" id="cite_ref-pmid18794803_4-0"><a href="#cite_note-pmid18794803-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> (See BRAF (gene)#Sorafenib for details the drug's interaction with B-Raf.)</p>

<p>Sorafenib treatment induces autophagy,<span class="mw-ref" id="cite_ref-pmid_=_24213221_5-0"><a href="#cite_note-pmid_=_24213221-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> which may suppress tumor growth. Based on its 1,3-disubstituted urea structure, Sorafenib is also a potent soluble epoxide hydrolase inhibitor and this activity likely reduces the severity of its adverse effects.<span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Sorafenib is indicated as a treatment for advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinomas (HCC) and thyroid cancer.<span class="mw-ref" id="cite_ref-MSR_7-0"><a href="#cite_note-MSR-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-DM_8-0"><a href="#cite_note-DM-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-EMC_9-0"><a href="#cite_note-EMC-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-TGA_10-0"><a href="#cite_note-TGA-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Kidney_cancer">Kidney cancer</h3></summary>
    
<p>Clinical trial results, published January 2007, showed that, compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear cell renal cell carcinoma in whom previous therapy has failed. The median progression-free survival was 5.5 months in the sorafenib group and 2.8 months in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55; P&lt;0.01).<span class="mw-ref" id="cite_ref-pmid17215530_11-0"><a href="#cite_note-pmid17215530-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>

<p>In Australia this is one of two TGA-labelled indications for sorafenib, although it is not listed on the Pharmaceutical Benefits Scheme for this indication.<span class="mw-ref" id="cite_ref-TGA_10-1"><a href="#cite_note-TGA-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-PBS_12-0"><a href="#cite_note-PBS-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Liver_cancer">Liver cancer</h3></summary>
    
<p>At ASCO 2007, results from the SHARP trial<span class="mw-ref" id="cite_ref-Llovet2008_13-0"><a href="#cite_note-Llovet2008-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> were presented, which showed efficacy of sorafenib in hepatocellular carcinoma. The primary endpoint was median overall survival, which showed a 44% improvement in patients who received sorafenib compared to placebo (hazard ratio 0.69; 95% CI, 0.55 to 0.87; p=0.0001). Both median survival and time to progression showed 3-month improvements; however, there was no significant difference in median time to symptomatic progression (<i>p</i>=0.77). There was no difference in quality of life measures, possibly attributable to toxicity of sorafenib or symptoms related to underlying progression of liver disease. Of note, this trial only included patients with Child-Pugh Class A (i.e. mildest) cirrhosis.<span class="mw-ref" id="cite_ref-Llovet2008_13-1"><a href="#cite_note-Llovet2008-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> Because of this trial Sorafenib obtained FDA approval for the treatment of advanced hepatocellular carcinoma in November 2007.<span class="mw-ref" id="cite_ref-Keeting2009_3-1"><a href="#cite_note-Keeting2009-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>

<p>In a randomized, double-blind, phase II trial combining sorafenib with <a href="Doxorubicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Doxorubicin" title="Doxorubicin">doxorubicin</a>, the median time to progression was not significantly delayed compared with doxorubicin alone in patients with advanced hepatocellular carcinoma. Median durations of overall survival and progression-free survival were significantly longer in patients receiving sorafenib plus doxorubicin than in those receiving doxorubicin alone.<span class="mw-ref" id="cite_ref-Keeting2009_3-2"><a href="#cite_note-Keeting2009-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>

<p>A prospective single-centre phase II study which included the patients with unresectable hepatocellular carcinoma (HCC)concluding that the combination of sorafenib and <span class="new">DEB</span>-TACE in patients with unresectable HCC is well tolerated and safe, with most toxicities related to sorafenib.<span class="mw-ref" id="cite_ref-pmid21911714_14-0"><a href="#cite_note-pmid21911714-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>

<p>In Australia this is the only indication for which sorafenib is listed on the PBS and hence the only Government-subsidised indication for sorafenib.<span class="mw-ref" id="cite_ref-PBS_12-1"><a href="#cite_note-PBS-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> Along with renal cell carcinoma, hepatocellular carcinoma is one of the TGA-labelled indications for sorafenib.<span class="mw-ref" id="cite_ref-TGA_10-2"><a href="#cite_note-TGA-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Thyroid_cancer">Thyroid cancer</h3></summary>
    
<p>On November 22, 2013, sorafenib was approved by the FDA for the treatment of locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment.<span class="mw-ref" id="cite_ref-FDA-2013-11_15-0"><a href="#cite_note-FDA-2013-11-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>

<p>The Phase 3 DECISION trial showed significant improvement in progression-free survival but not in overall survival. However, as is known, the side effects were very frequent, specially hand and foot skin reaction.<span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Desmoid_tumors">Desmoid tumors</h3></summary>
    
<p>A phase 3 clinical trial is under way testing the effectiveness of Sorafenib to treat desmoid tumors (also known as <b>aggressive fibromatosis</b>), after positive results in the first two trial stages. Dosage is typically half of that applied for malignant cancers (400<span>&nbsp;</span>mg vs 800<span>&nbsp;</span>mg). NCI are sponsoring this trial.<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<p><b><big>Adverse effects by frequency</big></b><br>
<i>Note: Potentially serious side effects are in <b>bold</b>.</i><br>
<b>Very common (&gt;10% frequency)</b><br></p>
<div class="div-col columns column-width" style="-moz-column-width: 18em; -webkit-column-width: 18em; column-width: 18em;   ">
<ul><li>Lymphopenia</li>
<li><b>Hypophosphataemia</b><span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 1;" data-mw-group="Note"><span class="mw-reflink-text">[Note 1]</span></a></span></li>
<li><b>Haemorrhage</b><span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 2;" data-mw-group="Note"><span class="mw-reflink-text">[Note 2]</span></a></span></li>
<li>Hypertension<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 3;" data-mw-group="Note"><span class="mw-reflink-text">[Note 3]</span></a></span></li>
<li>Diarrhea</li>
<li>Rash</li>
<li>Alopecia (hair loss; occurs in roughly 30% of patients receiving sorafenib)</li>
<li>Hand-foot syndrome</li>
<li>Pruritus (itchiness)</li>
<li>Erythema</li>
<li>Increased amylase</li>
<li>Increased lipase</li>
<li>Fatigue</li>
<li>Pain<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 4;" data-mw-group="Note"><span class="mw-reflink-text">[Note 4]</span></a></span></li>
<li>Nausea</li>
<li>Vomiting<span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 5;" data-mw-group="Note"><span class="mw-reflink-text">[Note 5]</span></a></span><span class="mw-ref" id="cite_ref-MSRCH_24-0"><a href="#cite_note-MSRCH-24" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></li></ul>
</div>

<p><b>Common (1-10% frequency)</b><br></p>
<div class="div-col columns column-width" style="-moz-column-width: 18em; -webkit-column-width: 18em; column-width: 18em;   "> 
<ul><li><b>Leucopenia</b><span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 6;" data-mw-group="Note"><span class="mw-reflink-text">[Note 6]</span></a></span></li>
<li><b>Neutropoenia</b><span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 7;" data-mw-group="Note"><span class="mw-reflink-text">[Note 7]</span></a></span></li>
<li><b>Anaemia</b><span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 8;" data-mw-group="Note"><span class="mw-reflink-text">[Note 8]</span></a></span></li>
<li><b>Thrombocytopenia</b><span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 9;" data-mw-group="Note"><span class="mw-reflink-text">[Note 9]</span></a></span></li>
<li>Anorexia (weight loss)</li>
<li><b>Hypocalcaemia</b><span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 10;" data-mw-group="Note"><span class="mw-reflink-text">[Note 10]</span></a></span></li>
<li><b>Hypokalaemia</b><span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 11;" data-mw-group="Note"><span class="mw-reflink-text">[Note 11]</span></a></span></li>
<li><b>Depression</b></li>
<li>Peripheral sensory neuropathy</li>
<li>Tinnitus<span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 12;" data-mw-group="Note"><span class="mw-reflink-text">[Note 12]</span></a></span></li>
<li><b>Congestive heart failure</b></li>
<li><b>Myocardial infarction</b><span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 13;" data-mw-group="Note"><span class="mw-reflink-text">[Note 13]</span></a></span></li>
<li><b>Myocardial ischaemia</b><span class="mw-ref" id="cite_ref-33"><a href="#cite_note-33" style="counter-reset: mw-Ref 14;" data-mw-group="Note"><span class="mw-reflink-text">[Note 14]</span></a></span></li>
<li>Hoarseness</li>
<li>Constipation</li>
<li>Stomatitis<span class="mw-ref" id="cite_ref-34"><a href="#cite_note-34" style="counter-reset: mw-Ref 15;" data-mw-group="Note"><span class="mw-reflink-text">[Note 15]</span></a></span></li>
<li>Dyspepsia<span class="mw-ref" id="cite_ref-35"><a href="#cite_note-35" style="counter-reset: mw-Ref 16;" data-mw-group="Note"><span class="mw-reflink-text">[Note 16]</span></a></span></li>
<li>Dysphagia<span class="mw-ref" id="cite_ref-36"><a href="#cite_note-36" style="counter-reset: mw-Ref 17;" data-mw-group="Note"><span class="mw-reflink-text">[Note 17]</span></a></span></li>
<li>Dry skin</li>
<li>Exfoliative dermatitis</li>
<li>Acne</li>
<li>Skin desquamation</li>
<li>Arthralgia<span class="mw-ref" id="cite_ref-37"><a href="#cite_note-37" style="counter-reset: mw-Ref 18;" data-mw-group="Note"><span class="mw-reflink-text">[Note 18]</span></a></span></li>
<li>Myalgia<span class="mw-ref" id="cite_ref-38"><a href="#cite_note-38" style="counter-reset: mw-Ref 19;" data-mw-group="Note"><span class="mw-reflink-text">[Note 19]</span></a></span></li>
<li><b>Kidney failure</b><span class="mw-ref" id="cite_ref-39"><a href="#cite_note-39" style="counter-reset: mw-Ref 20;" data-mw-group="Note"><span class="mw-reflink-text">[Note 20]</span></a></span></li>
<li>Proteinuria<span class="mw-ref" id="cite_ref-40"><a href="#cite_note-40" style="counter-reset: mw-Ref 21;" data-mw-group="Note"><span class="mw-reflink-text">[Note 21]</span></a></span></li>
<li>Erectile dysfunction</li>
<li>Asthenia (weakness)</li>
<li>Fever</li>
<li>Influenza-like illness</li></ul>
</div>
<ul><li>Transient increase in transaminase</li></ul>

<p><b>Uncommon (0.1-1% frequency)</b><br></p>
<div class="div-col columns column-width" style="-moz-column-width: 22em; -webkit-column-width: 22em; column-width: 22em;   ">
<ul><li>Folliculitis</li>
<li><b>Infection</b></li>
<li>Hypersensitivity reactions<span class="mw-ref" id="cite_ref-41"><a href="#cite_note-41" style="counter-reset: mw-Ref 22;" data-mw-group="Note"><span class="mw-reflink-text">[Note 22]</span></a></span></li>
<li><b>Hypothyroidism</b><span class="mw-ref" id="cite_ref-42"><a href="#cite_note-42" style="counter-reset: mw-Ref 23;" data-mw-group="Note"><span class="mw-reflink-text">[Note 23]</span></a></span></li>
<li><b>Hyperthyroidism</b><span class="mw-ref" id="cite_ref-43"><a href="#cite_note-43" style="counter-reset: mw-Ref 24;" data-mw-group="Note"><span class="mw-reflink-text">[Note 24]</span></a></span></li>
<li><b>Hyponatraemia</b><span class="mw-ref" id="cite_ref-44"><a href="#cite_note-44" style="counter-reset: mw-Ref 25;" data-mw-group="Note"><span class="mw-reflink-text">[Note 25]</span></a></span></li>
<li><b>Dehydration</b></li>
<li><b>Reversible posterior leukoencephalopathy</b></li>
<li><b>Hypertensive crisis</b></li>
<li>Rhinorrhoea<span class="mw-ref" id="cite_ref-45"><a href="#cite_note-45" style="counter-reset: mw-Ref 26;" data-mw-group="Note"><span class="mw-reflink-text">[Note 26]</span></a></span></li>
<li><b>Interstitial lung disease-like events</b><span class="mw-ref" id="cite_ref-46"><a href="#cite_note-46" style="counter-reset: mw-Ref 27;" data-mw-group="Note"><span class="mw-reflink-text">[Note 27]</span></a></span></li>
<li>Gastro-oesophageal reflux disease (GORD)</li>
<li><b>Pancreatitis</b><span class="mw-ref" id="cite_ref-47"><a href="#cite_note-47" style="counter-reset: mw-Ref 28;" data-mw-group="Note"><span class="mw-reflink-text">[Note 28]</span></a></span></li>
<li><b>Gastritis</b><span class="mw-ref" id="cite_ref-48"><a href="#cite_note-48" style="counter-reset: mw-Ref 29;" data-mw-group="Note"><span class="mw-reflink-text">[Note 29]</span></a></span></li>
<li><b>Gastrointestinal perforations</b><span class="mw-ref" id="cite_ref-49"><a href="#cite_note-49" style="counter-reset: mw-Ref 30;" data-mw-group="Note"><span class="mw-reflink-text">[Note 30]</span></a></span></li>
<li>Increase in <a href="Bilirubin.htm" tppabs="https://ptable.com/wiki/compounds/A/Bilirubin" title="Bilirubin">bilirubin</a> leading, potentially, to jaundice<span class="mw-ref" id="cite_ref-50"><a href="#cite_note-50" style="counter-reset: mw-Ref 31;" data-mw-group="Note"><span class="mw-reflink-text">[Note 31]</span></a></span></li>
<li><b>Cholecystitis</b><span class="mw-ref" id="cite_ref-51"><a href="#cite_note-51" style="counter-reset: mw-Ref 32;" data-mw-group="Note"><span class="mw-reflink-text">[Note 32]</span></a></span></li>
<li><b>Cholangitis</b><span class="mw-ref" id="cite_ref-52"><a href="#cite_note-52" style="counter-reset: mw-Ref 33;" data-mw-group="Note"><span class="mw-reflink-text">[Note 33]</span></a></span></li>
<li>Eczema</li>
<li><b>Erythema multiforme</b><span class="mw-ref" id="cite_ref-auto_53-0"><a href="#cite_note-auto-53" style="counter-reset: mw-Ref 34;" data-mw-group="Note"><span class="mw-reflink-text">[Note 34]</span></a></span></li>
<li><b>Keratoacanthoma</b><span class="mw-ref" id="cite_ref-54"><a href="#cite_note-54" style="counter-reset: mw-Ref 35;" data-mw-group="Note"><span class="mw-reflink-text">[Note 35]</span></a></span></li>
<li><b>Squamous cell carcinoma</b></li>
<li>Gynaecomastia (swelling of the breast tissue in men)</li>
<li><b>Transient increase in blood alkaline phosphatase</b></li>
<li><b>INR abnormal</b></li>
<li><b><a href="Thrombin.htm" tppabs="https://ptable.com/wiki/compounds/A/Prothrombin" title="Prothrombin" class="mw-redirect">Prothrombin</a> level abnormal</b></li>
<li><b>bulbous skin reaction</b><span class="mw-ref" id="cite_ref-55"><a href="#cite_note-55" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></li></ul>
</div>

<p><b>Rare (0.01-0.1% frequency)</b></p>
<div class="div-col columns column-width" style="-moz-column-width: 18em; -webkit-column-width: 18em; column-width: 18em;   ">
<ul><li><b>QT interval prolongation</b><span class="mw-ref" id="cite_ref-56"><a href="#cite_note-56" style="counter-reset: mw-Ref 36;" data-mw-group="Note"><span class="mw-reflink-text">[Note 36]</span></a></span></li>
<li><b>Angiooedema</b><span class="mw-ref" id="cite_ref-57"><a href="#cite_note-57" style="counter-reset: mw-Ref 37;" data-mw-group="Note"><span class="mw-reflink-text">[Note 37]</span></a></span></li>
<li><b>Anaphylactic reaction</b><span class="mw-ref" id="cite_ref-58"><a href="#cite_note-58" style="counter-reset: mw-Ref 38;" data-mw-group="Note"><span class="mw-reflink-text">[Note 38]</span></a></span></li>
<li><b>Hepatitis</b><span class="mw-ref" id="cite_ref-59"><a href="#cite_note-59" style="counter-reset: mw-Ref 39;" data-mw-group="Note"><span class="mw-reflink-text">[Note 39]</span></a></span></li>
<li>Radiation recall dermatitis</li>
<li><b>Stevens–Johnson syndrome</b><span class="mw-ref" id="cite_ref-auto_53-1"><a href="#cite_note-auto-53" style="counter-reset: mw-Ref 34;" data-mw-group="Note"><span class="mw-reflink-text">[Note 34]</span></a></span></li>
<li><b>Leucocytoclastic vasculitis</b></li>
<li><b>Toxic epidermal necrolysis</b><span class="mw-ref" id="cite_ref-auto_53-2"><a href="#cite_note-auto-53" style="counter-reset: mw-Ref 34;" data-mw-group="Note"><span class="mw-reflink-text">[Note 34]</span></a></span></li>
<li><b>Nephrotic syndrome</b></li>
<li><b>Rhabdomyolysis</b><span class="mw-ref" id="cite_ref-60"><a href="#cite_note-60" style="counter-reset: mw-Ref 40;" data-mw-group="Note"><span class="mw-reflink-text">[Note 40]</span></a></span></li></ul>
</div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Renal_cancer">Renal cancer</h3></summary>
    
<p>Sorafenib was approved by the U.S. Food and Drug Administration (FDA) in December 2005,<span class="mw-ref" id="cite_ref-FDAapproval1_61-0"><a href="#cite_note-FDAapproval1-61" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> and received European Commission marketing authorization in July 2006,<span class="mw-ref" id="cite_ref-EUapproval_62-0"><a href="#cite_note-EUapproval-62" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> both for use in the treatment of advanced renal cancer.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Liver_cancer_2">Liver cancer</h3></summary>
    
<p>The European Commission granted marketing authorization to the drug for the treatment of patients with hepatocellular carcinoma(HCC), the most common form of liver cancer, in October 2007,<span class="mw-ref" id="cite_ref-Euapproval_63-0"><a href="#cite_note-Euapproval-63" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> and FDA approval for this indication followed in November 2007.<span class="mw-ref" id="cite_ref-FDAapproval2_64-0"><a href="#cite_note-FDAapproval2-64" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></p>

<p>In November 2009, the UK's National Institute of Clinical Excellence declined to approve the drug for use within the NHS in England, Wales and Northern Ireland, stating that its effectiveness (increasing survival in primary liver cancer by 6 months) did not justify its high price, at up to £3000 per patient per month.<span class="mw-ref" id="cite_ref-bbc1_65-0"><a href="#cite_note-bbc1-65" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> In Scotland the drug had already been refused authorization by the Scottish Medicines Consortium for use within NHS Scotland, for the same reason.<span class="mw-ref" id="cite_ref-bbc1_65-1"><a href="#cite_note-bbc1-65" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>

<p>In March 2012, the Indian Patent Office granted a domestic company, Natco Pharma, a license to manufacture generic Sorafenib, bringing its price down by 97%. Bayer sells a month's supply, 120 tablets, of Nexavar for<span class="nowrap"><span style="white-space: nowrap">₹</span>280,000</span><span> (US$3,900)</span>. Natco Pharma will sell 120 tablets for <span class="nowrap"><span style="white-space: nowrap">₹</span>8,800</span><span> (US$120)</span>, while still paying a 6% royalty to Bayer. The royalty was later raised to 7% on appeal by Bayer.<span class="mw-ref" id="cite_ref-66"><a href="#cite_note-66" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span><span class="mw-ref" id="cite_ref-67"><a href="#cite_note-67" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span><span class="mw-ref" id="cite_ref-68"><a href="#cite_note-68" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span> Under the Patents Act, 1970 and the World Trade Organisation TRIPS Agreement, the government can issue a compulsory license when a drug is not available at an affordable price.<span class="mw-ref" id="cite_ref-India_Patents_(Amendment)_Act,_2005_69-0"><a href="#cite_note-India_Patents_(Amendment)_Act,_2005-69" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Lung">Lung</h3></summary>
    
<p>In some kinds of lung cancer (with squamous-cell histology) sorafenib administered in addition to <a href="Paclitaxel.htm" tppabs="https://ptable.com/wiki/compounds/A/Paclitaxel" title="Paclitaxel">paclitaxel</a> and <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Carboplatin  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Carboplatin'" tppabs="https://ptable.com/wiki/compounds/A/Carboplatin" title="Carboplatin">carboplatin</a> may be <i>detrimental</i> to patients.<span class="mw-ref" id="cite_ref-70"><a href="#cite_note-70" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Ovarian_cancer">Ovarian cancer</h3></summary>
    
<p>Sorafenib has been studied as maintenance therapy after ovarian cancer treatment and in combination with chemotherapy for recurrent ovarian cancer but did not show results that led to approval of the drug for these indications.<span class="mw-ref" id="cite_ref-71"><a href="#cite_note-71" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Brain_(recurrent_glioblastoma)">Brain (recurrent glioblastoma)</h3></summary>
    
<p>There is a phase I/II study at the Mayo Clinic<span class="mw-ref" id="cite_ref-Mayo_72-0"><a href="#cite_note-Mayo-72" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span> of sorafenib and CCI-779 (<a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">temsirolimus</a>) for recurrent glioblastoma. </p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Desmoid_tumor_(aggressive_fibromatosis)">Desmoid tumor (aggressive fibromatosis)</h3></summary>
    
<p>A study performed in 2011 showed that Sorafenib is active against aggressive fibromatosis. This study is being used as justification for using Sorafenib as an initial course of treatment in some patients with aggressive fibromatosis.<span class="mw-ref" id="cite_ref-73"><a href="#cite_note-73" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Nexavar_controversy">Nexavar controversy</h2></summary>
    

<p>In January 2014, Bayer's CEO Marijn Dekkers allegedly stated that Nexavar was developed for "Western Patients Who Can Afford it, not for Indians". However, Dekkers actually never said this. In fact, his words were misquoted and the context was omitted.  A kidney cancer patient would pay $96,000 (£58,000) for a year's course of the Bayer-made drug, whereas the cost of the Indian version of the generic drug would be around $2,800 (£1,700).&gt;<span class="mw-ref" id="cite_ref-74"><a href="#cite_note-74" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Notes">Notes</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references" data-mw-group="Note"><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text">Low blood phosphate levels</span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text">Bleeding; including serious bleeds such as intracranial and intrapulmonary bleeds</span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text">High blood pressure</span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text">Including abdominal pain, headache, tumour pain, etc.</span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text">Considered a low (~10-30%) risk chemotherapeutic agent for causing emesis)</span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text">Low level of white blood cells in the blood</span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text">Low level of neutrophils in the blood</span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text">Low level of red blood cells in the blood</span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text">Low level of plasma cells in the blood</span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text">Low blood <a href="Calcium.htm" tppabs="https://ptable.com/wiki/compounds/A/Calcium" title="Calcium">calcium</a></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text">Low blood <a href="Potassium.htm" tppabs="https://ptable.com/wiki/compounds/A/Potassium" title="Potassium">potassium</a></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text">Hearing ringing in the ears</span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text">Heart attack</span></li><li id="cite_note-33"> <span id="mw-reference-text-cite_note-33" class="mw-reference-text">Lack of blood supply for the heart muscle</span></li><li id="cite_note-34"> <span id="mw-reference-text-cite_note-34" class="mw-reference-text">Mouth swelling, also dry mouth and glossodynia</span></li><li id="cite_note-35"> <span id="mw-reference-text-cite_note-35" class="mw-reference-text">Indigestion</span></li><li id="cite_note-36"> <span id="mw-reference-text-cite_note-36" class="mw-reference-text">Not being able to swallow</span></li><li id="cite_note-37"> <span id="mw-reference-text-cite_note-37" class="mw-reference-text">Sore joints</span></li><li id="cite_note-38"> <span id="mw-reference-text-cite_note-38" class="mw-reference-text">Muscle aches</span></li><li id="cite_note-39"> <span id="mw-reference-text-cite_note-39" class="mw-reference-text">Kidney failure</span></li><li id="cite_note-40"> <span id="mw-reference-text-cite_note-40" class="mw-reference-text">Excreting protein [usually plasma proteins] in the urine. Not dangerous in itself but it is indicative kidney damage</span></li><li id="cite_note-41"> <span id="mw-reference-text-cite_note-41" class="mw-reference-text">Including skin reactions and urticaria (hives)</span></li><li id="cite_note-42"> <span id="mw-reference-text-cite_note-42" class="mw-reference-text">Underactive thyroid</span></li><li id="cite_note-43"> <span id="mw-reference-text-cite_note-43" class="mw-reference-text">Overactive thyroid</span></li><li id="cite_note-44"> <span id="mw-reference-text-cite_note-44" class="mw-reference-text">Low blood sodium</span></li><li id="cite_note-45"> <span id="mw-reference-text-cite_note-45" class="mw-reference-text">Runny nose</span></li><li id="cite_note-46"> <span id="mw-reference-text-cite_note-46" class="mw-reference-text">Pneumonitis, radiation pneumonitis, acute respiratory distress, etc.</span></li><li id="cite_note-47"> <span id="mw-reference-text-cite_note-47" class="mw-reference-text">Swelling of the pancreas</span></li><li id="cite_note-48"> <span id="mw-reference-text-cite_note-48" class="mw-reference-text">Swelling of the stomach</span></li><li id="cite_note-49"> <span id="mw-reference-text-cite_note-49" class="mw-reference-text">Formation of a hole in the gastrointestinal tract, leading to potentially fatal bleeds</span></li><li id="cite_note-50"> <span id="mw-reference-text-cite_note-50" class="mw-reference-text">Yellowing of the skin and eyes due to a failure of the liver to adequately cope with the amount of bilirubin produced by the day-to-day actions of the body</span></li><li id="cite_note-51"> <span id="mw-reference-text-cite_note-51" class="mw-reference-text">Swelling of the gallbladder</span></li><li id="cite_note-52"> <span id="mw-reference-text-cite_note-52" class="mw-reference-text">Swelling of the bile duct</span></li><li id="cite_note-auto-53"> <span id="mw-reference-text-cite_note-auto-53" class="mw-reference-text">A potentially fatal skin reaction</span></li><li id="cite_note-54"> <span id="mw-reference-text-cite_note-54" class="mw-reference-text">A fairly benign form of skin cancer</span></li><li id="cite_note-56"> <span id="mw-reference-text-cite_note-56" class="mw-reference-text">A potentially fatal abnormality in the electrical activity of the heart</span></li><li id="cite_note-57"> <span id="mw-reference-text-cite_note-57" class="mw-reference-text">Swelling of the skin and mucous membranes</span></li><li id="cite_note-58"> <span id="mw-reference-text-cite_note-58" class="mw-reference-text">A potentially fatal allergic reaction</span></li><li id="cite_note-59"> <span id="mw-reference-text-cite_note-59" class="mw-reference-text">Swelling of the liver</span></li><li id="cite_note-60"> <span id="mw-reference-text-cite_note-60" class="mw-reference-text">The rapid breakdown of muscle tissue leading to the build-up of myoglobin in the blood and resulting in damage to the kidneys</span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-1"> <span id="mw-reference-text-cite_note-1" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109030.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109030.htm'" tppabs="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109030.htm" class="external text external">"FDA Approves Nexavar for Patients with Inoperable Liver Cancer"</a> (Press release). FDA. November 19, 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">November 10,</span> 2012</span>.</cite></span></li><li id="cite_note-pmid18852116-2"> <span id="mw-reference-text-cite_note-pmid18852116-2" class="mw-reference-text"><cite id="CITEREFWilhelmAdnaneNewellVillanueva2008" class="citation journal cs1">Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M (October 2008). <a href="javascript:if(confirm('https://doi.org/10.1158/1535-7163.MCT-08-0013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1158/1535-7163.MCT-08-0013'" tppabs="https://doi.org/10.1158/1535-7163.MCT-08-0013" class="external text external">"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling"</a>. <i>Mol Cancer Ther</i>. <b>7</b> (10): 3129–40. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1158%2F1535-7163.MCT-08-0013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1158%2F1535-7163.MCT-08-0013'" tppabs="https://doi.org/10.1158%2F1535-7163.MCT-08-0013" class="external text external">10.1158/1535-7163.MCT-08-0013</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18852116  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18852116'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18852116" class="external text external">18852116</a>.</cite></span></li><li id="cite_note-Keeting2009-3"> <span id="mw-reference-text-cite_note-Keeting2009-3" class="mw-reference-text"><cite id="CITEREFKeatingSantoro2009" class="citation journal cs1">Keating GM, Santoro A (2009). "Sorafenib: a review of its use in advanced hepatocellular carcinoma". <i>Drugs</i>. <b>69</b> (2): 223–40. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003495-200969020-00006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003495-200969020-00006'" tppabs="https://doi.org/10.2165%2F00003495-200969020-00006" class="external text external">10.2165/00003495-200969020-00006</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19228077  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19228077'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19228077" class="external text external">19228077</a>.</cite></span></li><li id="cite_note-pmid18794803-4"> <span id="mw-reference-text-cite_note-pmid18794803-4" class="mw-reference-text"><cite id="CITEREFSmalleyXiaoVillanuevaNguyen2009" class="citation journal cs1">Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M (January 2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898184  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898184'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898184" class="external text external">"CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations"</a>. <i>Oncogene</i>. <b>28</b> (1): 85–94. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fonc.2008.362  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fonc.2008.362'" tppabs="https://doi.org/10.1038%2Fonc.2008.362" class="external text external">10.1038/onc.2008.362</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898184  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898184'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898184" class="external text external">2898184</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18794803  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18794803'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18794803" class="external text external">18794803</a>.</cite></span></li><li id="cite_note-pmid_=_24213221-5"> <span id="mw-reference-text-cite_note-pmid_=_24213221-5" class="mw-reference-text"><cite id="CITEREFZhang_Y2014" class="citation journal cs1">Zhang Y (Jan 2014). <a href="javascript:if(confirm('https://doi.org/10.3892/mmr.2013.1781  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3892/mmr.2013.1781'" tppabs="https://doi.org/10.3892/mmr.2013.1781" class="external text external">"Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways"</a>. <i>Mol Med Rep</i>. <b>9</b> (1): 83–90. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.3892%2Fmmr.2013.1781  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3892%2Fmmr.2013.1781'" tppabs="https://doi.org/10.3892%2Fmmr.2013.1781" class="external text external">10.3892/mmr.2013.1781</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24213221  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24213221'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24213221" class="external text external">24213221</a>.</cite></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text"><cite id="CITEREFSinghHammock2020" class="citation book cs1">Singh, Nalin; Hammock, Bruce (March 30, 2020). "Soluble Epoxide Hydrolase".  In Offermanns, Stefan; Rosenthal, Walter (eds.). <i>Encyclopedia of Molecular Pharmacology</i>. Springer, Cham. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-030-21573-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-030-21573-6'" tppabs="https://doi.org/10.1007%2F978-3-030-21573-6" class="external text external">10.1007/978-3-030-21573-6</a>. ISBN<span>&nbsp;</span><bdi>978-3-030-21573-6</bdi>.</cite></span></li><li id="cite_note-MSR-7"> <span id="mw-reference-text-cite_note-MSR-7" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://reference.medscape.com/drug/nexavar-sorafenib-342260  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://reference.medscape.com/drug/nexavar-sorafenib-342260#showall'" tppabs="http://reference.medscape.com/drug/nexavar-sorafenib-342260#showall" class="external text external">"Nexavar (sorafenib) dosing, indications, interactions, adverse effects, and more"</a>. <i>Medscape Reference</i>. WebMD<span class="reference-accessdate">. Retrieved <span class="nowrap">26 December</span> 2013</span>.</cite></span></li><li id="cite_note-DM-8"> <span id="mw-reference-text-cite_note-DM-8" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0'" tppabs="http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0" class="external text external">"Nexavar (sorafenib) tablet, film coated <span>[</span>Bayer HealthCare Pharmaceuticals Inc.<span>]</span>"</a>. <i>DailyMed</i>. Bayer HealthCare Pharmaceuticals Inc. November 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">26 December</span> 2013</span>.</cite></span></li><li id="cite_note-EMC-9"> <span id="mw-reference-text-cite_note-EMC-9" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.medicines.org.uk/emc/medicine/18520/SPC/Nexavar+200mg+film-coated+tablets/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medicines.org.uk/emc/medicine/18520/SPC/Nexavar+200mg+film-coated+tablets/'" tppabs="http://www.medicines.org.uk/emc/medicine/18520/SPC/Nexavar+200mg+film-coated+tablets/" class="external text external">"Nexavar 200mg film-coated tablets - Summary of Product Characteristics (SPC) - (eMC)"</a>. <i>electronic Medicines Compendium</i>. Bayer plc. 27 March 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">26 December</span> 2013</span>.</cite></span></li><li id="cite_note-TGA-10"> <span id="mw-reference-text-cite_note-TGA-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07403-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07403-3'" tppabs="https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07403-3" class="external text external">"PRODUCT INFORMATION NEXAVAR (sorafenib tosylate)"</a> <span class="cs1-format">(PDF)</span>. <i>TGA eBusiness Services</i>. Bayer Australia Ltd. 12 December 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">26 December</span> 2013</span>.</cite></span></li><li id="cite_note-pmid17215530-11"> <span id="mw-reference-text-cite_note-pmid17215530-11" class="mw-reference-text"><cite id="CITEREFEscudier,_BEisen,_TStadler,_WMSzczylik,_C2007" class="citation journal cs1">Escudier, B; Eisen, T; Stadler, WM; Szczylik, C; Oudard, S; Siebels, M; Negrier, S; Chevreau, C; Solska, E; Desai, AA; Rolland, F; Demkow, T; Hutson, TE; Gore, M; Freeman, S; Schwartz, B; Shan, M; Simantov, R; Bukowski, RM (January 2007). "Sorafenib in advanced clear-cell renal-cell carcinoma". <i>New England Journal of Medicine</i>. <b>356</b> (2): 125–34. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa060655  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa060655'" tppabs="https://doi.org/10.1056%2FNEJMoa060655" class="external text external">10.1056/NEJMoa060655</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17215530  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17215530'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17215530" class="external text external">17215530</a>.</cite></span></li><li id="cite_note-PBS-12"> <span id="mw-reference-text-cite_note-PBS-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.pbs.gov.au/medicine/item/9380Q  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pbs.gov.au/medicine/item/9380Q'" tppabs="http://www.pbs.gov.au/medicine/item/9380Q" class="external text external">"Pharmaceutical Benefits Scheme (PBS) -SORAFENIB"</a>. <i>Pharmaceutical Benefits Scheme</i>. Australian Government Department of Health<span class="reference-accessdate">. Retrieved <span class="nowrap">27 December</span> 2013</span>.</cite></span></li><li id="cite_note-Llovet2008-13"> <span id="mw-reference-text-cite_note-Llovet2008-13" class="mw-reference-text"><cite id="CITEREFLlovet2008" class="citation journal cs1">Llovet;  et al. (2008). "Sorafenib in Advanced Hepatocellular Carcinoma". <i>New England Journal of Medicine</i>. <b>359</b> (4): 378–90. CiteSeerX<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.531.1130  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.531.1130'" tppabs="https://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.531.1130" class="external text external">10.1.1.531.1130</a></span>. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa0708857  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa0708857'" tppabs="https://doi.org/10.1056%2FNEJMoa0708857" class="external text external">10.1056/NEJMoa0708857</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18650514  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18650514'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18650514" class="external text external">18650514</a>.</cite></span></li><li id="cite_note-pmid21911714-14"> <span id="mw-reference-text-cite_note-pmid21911714-14" class="mw-reference-text"><cite id="CITEREFPawlikReyesCosgroveKamel2011" class="citation journal cs1">Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF (October 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829081  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829081'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829081" class="external text external">"Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma"</a>. <i>J. Clin. Oncol</i>. <b>29</b> (30): 3960–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1200%2FJCO.2011.37.1021  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1200%2FJCO.2011.37.1021'" tppabs="https://doi.org/10.1200%2FJCO.2011.37.1021" class="external text external">10.1200/JCO.2011.37.1021</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829081  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829081'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829081" class="external text external">4829081</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21911714  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21911714'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21911714" class="external text external">21911714</a>.</cite></span></li><li id="cite_note-FDA-2013-11-15"> <span id="mw-reference-text-cite_note-FDA-2013-11-15" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.cancer.gov/cancertopics/druginfo/fda-sorafenib-tosylate  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cancer.gov/cancertopics/druginfo/fda-sorafenib-tosylate'" tppabs="http://www.cancer.gov/cancertopics/druginfo/fda-sorafenib-tosylate" class="external text external">"FDA Approval for Sorafenib Tosylate"</a>. <i>National Cancer Institute</i>. 5 October 2006.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.medpagetoday.com/meetingcoverage/asco/39545  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medpagetoday.com/meetingcoverage/asco/39545'" tppabs="https://www.medpagetoday.com/meetingcoverage/asco/39545" class="external text external">"ASCO: Sorafenib Halts Resistant Thyroid Cancer"</a>. <i>www.medpagetoday.com</i>. 4 June 2013.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://clinicaltrials.gov/show/NCT02066181  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://clinicaltrials.gov/show/NCT02066181'" tppabs="http://clinicaltrials.gov/show/NCT02066181" class="external text external">"Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis"</a>. <i>Clinicaltrials.gov</i>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite id="CITEREFGounderLefkowitzKeohanD'Adamo2011" class="citation journal cs1">Gounder, MM; Lefkowitz, RA; Keohan, ML; D'Adamo, DR; Hameed, M; Antonescu, CR; Singer, S; Stout, K; Ahn, L; Maki, RG (15 June 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981" class="external text external">"Activity of Sorafenib against desmoid tumor/deep fibromatosis"</a>. <i>Clinical Cancer Research</i>. <b>17</b> (12): 4082–90. doi:<a href="javascript:if(confirm('https://doi.org/10.1158%2F1078-0432.ccr-10-3322  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1158%2F1078-0432.ccr-10-3322'" tppabs="https://doi.org/10.1158%2F1078-0432.ccr-10-3322" class="external text external">10.1158/1078-0432.ccr-10-3322</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981" class="external text external">3152981</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21447727  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21447727'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21447727" class="external text external">21447727</a>.</cite></span></li><li id="cite_note-MSRCH-24"> <span id="mw-reference-text-cite_note-MSRCH-24" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://emedicine.medscape.com/article/1355706-treatment  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://emedicine.medscape.com/article/1355706-treatment#showall'" tppabs="http://emedicine.medscape.com/article/1355706-treatment#showall" class="external text external">"Chemotherapy-Induced Nausea and Vomiting Treatment &amp; Management"</a>. <i>Medscape Reference</i>. WebMD. 3 July 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">26 December</span> 2013</span>.</cite></span></li><li id="cite_note-55"> <span id="mw-reference-text-cite_note-55" class="mw-reference-text"><cite id="CITEREFHagopian2010" class="citation journal cs1">Hagopian, Benjamin (August 2010). <a href="javascript:if(confirm('https://doi.org/10.4021/jmc112e  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4021/jmc112e'" tppabs="https://doi.org/10.4021/jmc112e" class="external text external">"Unusually Severe Bullous Skin Reaction to Sorafenib: A Case Report"</a>. <i>Journal of Medical Cases</i>. <b>1</b> (1): 1–3. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.4021%2Fjmc112e  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4021%2Fjmc112e'" tppabs="https://doi.org/10.4021%2Fjmc112e" class="external text external">10.4021/jmc112e</a></span>.</cite></span></li><li id="cite_note-FDAapproval1-61"> <span id="mw-reference-text-cite_note-FDAapproval1-61" class="mw-reference-text"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021923ltr.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021923ltr.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021923ltr.pdf" class="external text external">FDA Approval letter for use of sorafenib in advanced renal cancer</a></span></li><li id="cite_note-EUapproval-62"> <span id="mw-reference-text-cite_note-EUapproval-62" class="mw-reference-text">European Commission<span>&nbsp;</span>– Enterprise and industry. <a href="javascript:if(confirm('http://ec.europa.eu/enterprise/pharmaceuticals/register/h342.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://ec.europa.eu/enterprise/pharmaceuticals/register/h342.htm'" tppabs="http://ec.europa.eu/enterprise/pharmaceuticals/register/h342.htm" class="external text external">Nexavar</a> <a href="javascript:if(confirm('https://web.archive.org/web/20080201001404/http://ec.europa.eu/enterprise/pharmaceuticals/register/h342.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20080201001404/http://ec.europa.eu/enterprise/pharmaceuticals/register/h342.htm'" tppabs="https://web.archive.org/web/20080201001404/http://ec.europa.eu/enterprise/pharmaceuticals/register/h342.htm" class="external text external">Archived</a><span> 2008-02-01 at the </span>Wayback Machine. Retrieved April 24, 2007.</span></li><li id="cite_note-Euapproval-63"> <span id="mw-reference-text-cite_note-Euapproval-63" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20120206215725/http://www.pslgroup.com/news/content.nsf/medicalnews/852571020057CCF685257384005A45B1?OpenDocument&id=&count=10  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120206215725/http://www.pslgroup.com/news/content.nsf/medicalnews/852571020057CCF685257384005A45B1?OpenDocument&id=&count=10'" tppabs="https://web.archive.org/web/20120206215725/http://www.pslgroup.com/news/content.nsf/medicalnews/852571020057CCF685257384005A45B1?OpenDocument&id=&count=10" class="external text external">"Nexavar (Sorafenib) Approved for Hepatocellular Carcinoma in Europe"</a> (Press release). Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals. October 30, 2007. Archived from <a href="javascript:if(confirm('http://www.pslgroup.com/news/content.nsf/medicalnews/852571020057CCF685257384005A45B1?OpenDocument&id=&count=10  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pslgroup.com/news/content.nsf/medicalnews/852571020057CCF685257384005A45B1?OpenDocument&id=&count=10'" tppabs="http://www.pslgroup.com/news/content.nsf/medicalnews/852571020057CCF685257384005A45B1?OpenDocument&id=&count=10" class="external text external">the original</a> on February 6, 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">November 10,</span> 2012</span>.</cite></span></li><li id="cite_note-FDAapproval2-64"> <span id="mw-reference-text-cite_note-FDAapproval2-64" class="mw-reference-text"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021923s004,s005,s006,s007.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021923s004,s005,s006,s007.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021923s004,s005,s006,s007.pdf" class="external text external">FDA Approval letter for use of sorafenib in inoperable hepatocellular carcinoma</a></span></li><li id="cite_note-bbc1-65"> <span id="mw-reference-text-cite_note-bbc1-65" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://news.bbc.co.uk/1/hi/health/8367614.stm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://news.bbc.co.uk/1/hi/health/8367614.stm'" tppabs="http://news.bbc.co.uk/1/hi/health/8367614.stm" class="external text external">"Liver drug 'too expensive<span class="cs1-kern-right">'</span>"</a>. BBC News. November 19, 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">November 10,</span> 2012</span>.</cite></span></li><li id="cite_note-66"> <span id="mw-reference-text-cite_note-66" class="mw-reference-text"><a href="javascript:if(confirm('http://www.lawyerscollective.org/updates/supreme-court-says-no-to-bayer-upholds-compulsory-license-on-nexavar.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.lawyerscollective.org/updates/supreme-court-says-no-to-bayer-upholds-compulsory-license-on-nexavar.html'" tppabs="http://www.lawyerscollective.org/updates/supreme-court-says-no-to-bayer-upholds-compulsory-license-on-nexavar.html" class="external free external">http://www.lawyerscollective.org/updates/supreme-court-says-no-to-bayer-upholds-compulsory-license-on-nexavar.html</a></span></li><li id="cite_note-67"> <span id="mw-reference-text-cite_note-67" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20120321173251/http://www.ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120321173251/http://www.ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf'" tppabs="https://web.archive.org/web/20120321173251/http://www.ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf" class="external text external">"Archived copy"</a> <span class="cs1-format">(PDF)</span>. Archived from <a href="javascript:if(confirm('http://www.ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf'" tppabs="http://www.ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2012-03-21<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-04-02</span></span>.</cite><span class="cs1-maint citation-comment">CS1 maint: archived copy as title (link)</span></span></li><li id="cite_note-68"> <span id="mw-reference-text-cite_note-68" class="mw-reference-text"><cite class="citation journal cs1"><a href="javascript:if(confirm('https://doi.org/10.1038/483250a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038/483250a'" tppabs="https://doi.org/10.1038/483250a" class="external text external">"Seven days: 9–15 March 2012"</a>. <i>Nature</i>. <b>483</b> (7389): 250–1. 2012. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2012Natur.483..250.  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2012Natur.483..250.'" tppabs="https://ui.adsabs.harvard.edu/abs/2012Natur.483..250." class="external text external">2012Natur.483..250.</a>. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1038%2F483250a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2F483250a'" tppabs="https://doi.org/10.1038%2F483250a" class="external text external">10.1038/483250a</a></span>.</cite></span></li><li id="cite_note-India_Patents_(Amendment)_Act,_2005-69"> <span id="mw-reference-text-cite_note-India_Patents_(Amendment)_Act,_2005-69" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.wipo.int/wipolex/en/text.jsp?file_id=128116  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.wipo.int/wipolex/en/text.jsp?file_id=128116'" tppabs="http://www.wipo.int/wipolex/en/text.jsp?file_id=128116" class="external text external">"India Patents (Amendment) Act, 2005"</a>. WIPO<span class="reference-accessdate">. Retrieved <span class="nowrap">16 January</span> 2013</span>.</cite></span></li><li id="cite_note-70"> <span id="mw-reference-text-cite_note-70" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.medscape.com/viewarticle/573511  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.medscape.com/viewarticle/573511'" tppabs="http://www.medscape.com/viewarticle/573511" class="external text external">"Addition of Sorafenib May Be Detrimental in Some Lung Cancer Patients"</a>. <i>login.medscape.com</i>.</cite></span></li><li id="cite_note-71"> <span id="mw-reference-text-cite_note-71" class="mw-reference-text"><cite id="CITEREFCicconeMaozCasabarMachida2016" class="citation journal cs1">Ciccone, Marcia A.; Maoz, Asaf; Casabar, Jennifer K.; Machida, Hiroko; Mabuchi, Seiji; Matsuo, Koji (July 2016). "Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature". <i>Expert Opinion on Investigational Drugs</i>. <b>25</b> (7): 781–796. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F13543784.2016.1181748  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F13543784.2016.1181748'" tppabs="https://doi.org/10.1080%2F13543784.2016.1181748" class="external text external">10.1080/13543784.2016.1181748</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1744-7658  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1744-7658'" tppabs="https://www.worldcat.org/issn/1744-7658" class="external text external">1744-7658</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27101098  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27101098'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27101098" class="external text external">27101098</a>.</cite></span></li><li id="cite_note-Mayo-72"> <span id="mw-reference-text-cite_note-Mayo-72" class="mw-reference-text"><span>Clinical trial number </span><i><a href="javascript:if(confirm('https://www.clinicaltrials.gov/show/NCT00329719  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.clinicaltrials.gov/show/NCT00329719'" tppabs="https://www.clinicaltrials.gov/show/NCT00329719" class="external text external">NCT00329719</a></i><span> for "Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma" at </span>ClinicalTrials.gov</span></li><li id="cite_note-73"> <span id="mw-reference-text-cite_note-73" class="mw-reference-text"><cite class="citation journal cs1">Gounder, MM; Lefkowitz, RA; Keohan, ML; D'Adamo, DR; Hameed, M; Antonescu, CR; Singer, S; Stout, K; Ahn, L; Maki, RG (Jun 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981" class="external text external">"Activity of Sorafenib against desmoid tumor/deep fibromatosis"</a>. <i>Clin Cancer Res</i>. <b>17</b> (12): 4082–90. doi:<a href="javascript:if(confirm('https://doi.org/10.1158%2F1078-0432.CCR-10-3322  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1158%2F1078-0432.CCR-10-3322'" tppabs="https://doi.org/10.1158%2F1078-0432.CCR-10-3322" class="external text external">10.1158/1078-0432.CCR-10-3322</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152981" class="external text external">3152981</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21447727  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21447727'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21447727" class="external text external">21447727</a>.</cite></span></li><li id="cite_note-74"> <span id="mw-reference-text-cite_note-74" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://archives.cjr.org/the_audit/bloombergs_viral_misquote_1.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archives.cjr.org/the_audit/bloombergs_viral_misquote_1.php'" tppabs="https://archives.cjr.org/the_audit/bloombergs_viral_misquote_1.php" class="external text external">"Bloomberg's viral misquote"</a>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/sorafenib  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/sorafenib'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/sorafenib" class="external text external">"Sorafenib"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li>
<li><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sorafenib-tosylate  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sorafenib-tosylate'" tppabs="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sorafenib-tosylate" class="external text external">"Sorafenib"</a>. <i>National Cancer Institute</i>.</cite></li>
<li><span>Clinical trial number </span><i><a href="javascript:if(confirm('https://www.clinicaltrials.gov/show/NCT00217399  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.clinicaltrials.gov/show/NCT00217399'" tppabs="https://www.clinicaltrials.gov/show/NCT00217399" class="external text external">NCT00217399</a></i><span> for "Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer" at </span>ClinicalTrials.gov</li></ul>

<div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em">Targeted cancer therapy / antineoplastic agents (L01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">CI monoclonal antibodies ("-mab")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (<a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Panitumumab)</li>
<li><i>HER2/neu</i> (Pertuzumab, <a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (+hyaluronidase)</li>
<li>Trastuzumab emtansine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>EpCAM</i> (Catumaxomab</li>
<li>Edrecolomab)</li>
<li><i>VEGF-A</i> (Bevacizumab)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Leukemia/lymphoma</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>lymphoid: <i>CD20</i> (<a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li>
<li>Obinutuzumab</li>
<li>Ofatumumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a>), <i>CD30</i> (Brentuximab), <i>CD52</i> (<a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul>

<ul><li>myeloid: <i>CD33</i> (Gemtuzumab)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Tyrosine kinase inhibitors ("-nib")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (Brigatinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Olmutinib</li>
<li>Osimertinib</li>
<li>Rociletinib</li>
<li>Vandetanib)</li>
<li><i>HER1/EGFR and HER2/neu</i>
<ul><li>Afatinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li></ul></li></ul>

<ul><li>RTK class III: <i>C-kit and PDGFR</i> (Axitinib</li>
<li>Masitinib</li>
<li>Pazopanib</li>
<li>Ripretinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib)</li>
<li><i>FLT3</i> (Lestaurtinib)</li></ul>

<ul><li><i>VEGFR</i>
<ul><li>Axitinib</li>
<li>Cediranib</li>
<li>Lenvatinib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Tivozanib</li>
<li>Toceranib</li>
<li>Vandetanib</li></ul></li></ul>

<ul><li><i>ALK</i> 
<ul><li>Alectinib</li>
<li>Brigatinib</li>
<li>Ceritinib</li></ul></li></ul>

<p><i>RET inhibitors:</i> Entrectinib (ALK, ROS1, NTRK), Pemigatinib (FGFR), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).
<i>c-MET inhibitors:</i> Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)</p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-receptor</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>bcr-abl</i>
<ul><li>Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Nilotinib</li>
<li>Ponatinib</li>
<li>Radotinib</li></ul></li></ul>

<ul><li><i>Src</i> (Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul>

<ul><li><i>Janus kinase</i>
<ul><li>Lestaurtinib</li>
<li>Momelotinib</li>
<li>Pacritinib</li>
<li>Ruxolitinib</li></ul></li></ul>

<ul><li><i>MAP2K</i>
<ul><li>Binimetinib</li>
<li>Cobimetinib</li>
<li>Selumetinib</li>
<li>Trametinib</li></ul></li></ul>

<ul><li><i>EML4-ALK</i>
<ul><li>Crizotinib</li>
<li>Entrectinib</li>
<li>Lorlatinib</li></ul></li></ul>

<ul><li><i>Bruton's</i>
<ul><li>Acalabrutinib</li>
<li>Ibrutinib</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>fusion protein against VEGF</i> (Aflibercept)</li>
<li><i>proapoptotic peptide against ANXA2 and prohibitin</i> (Adipotide)</li>
<li><i>exotoxin against <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="Denileukin_diftitox.htm" tppabs="https://ptable.com/wiki/compounds/A/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li>
<li><i>mTOR inhibitors</i>
<ul><li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li>
<li><i>hedgehog inhibitors</i>
<ul><li>Sonidegib</li>
<li>Vismodegib</li></ul></li>
<li><i>CDK inhibitor</i> (Palbociclib</li>
<li>Ribociclib)</li>
<li>Venetoclax</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Cytokine_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Cytokine_receptor_modulators" style="font-size:114%;margin:0 4em">Cytokine receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chemokine</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CSF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Erythropoietin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">ARA-290</span></li>
<li><span class="new">Asialo erythropoietin</span></li>
<li><span class="new">Carbamylated erythropoietin</span></li>
<li><span class="new">CNTO-530</span></li>
<li><a href="Darbepoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Darbepoetin_alfa" title="Darbepoetin alfa">Darbepoetin alfa</a></li>
<li><a href="Epoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Epoetin_alfa" title="Epoetin alfa">Epoetin alfa</a></li>
<li>Epoetin beta</li>
<li><span class="new">Epoetin delta</span></li>
<li><span class="new">Epoetin epsilon</span></li>
<li><span class="new">Epoetin gamma</span></li>
<li><span class="new">Epoetin kappa</span></li>
<li><span class="new">Epoetin omega</span></li>
<li><span class="new">Epoetin theta</span></li>
<li>Epoetin zeta</li>
<li>Erythropoietin (EPO)</li>
<li><span class="new">Erythropoietin-Fc</span></li>
<li>Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)</li>
<li>Peginesatide</li>
<li><span class="new">Pegol sihematide (EPO-018B)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">G-CSF (CSF3)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Filgrastim" title="Filgrastim">Filgrastim</a></li>
<li>Granulocyte colony-stimulating factor</li>
<li>Lenograstim</li>
<li><span class="new">Leridistim</span></li>
<li>Lipegfilgrastim</li>
<li><span class="new">Nartograstim</span></li>
<li><a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">Pegfilgrastim</a></li>
<li><span class="new">Pegnartograstim</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GM-CSF (CSF2)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ecogramostim</span></li>
<li>Granulocyte macrophage colony-stimulating factor</li>
<li><span class="new">Milodistim</span></li>
<li>Molgramostim</li>
<li><span class="new">Regramostim</span></li>
<li><a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a></li></ul>

<ul><li><i>Antibodies:</i> Mavrilimumab</li>
<li>Namilumab</li>
<li>Otilimab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">M-CSF (CSF1)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Cilmostim</span></li>
<li>Interleukin-34</li>
<li><span class="new">Lanimostim</span></li>
<li>Macrophage colony-stimulating factor</li>
<li><span class="new">Mirimostim</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Thrombopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Eltrombopag</li>
<li><span class="new">Pegacaristim</span></li>
<li>Promegapoietin</li>
<li>Romiplostim</li>
<li>Thrombopoietin (THPO, MGDF)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Interferon</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNAR (α/β, I)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Albinterferon</li>
<li>Interferon alpha (interferon alfa, IFN-α)</li>
<li>Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)</li>
<li><span class="new">Interferon alfa 2a</span></li>
<li>Interferon alfa 2b</li>
<li><span class="new">Interferon alfa n1</span></li>
<li><a href="Interferon_alfacon-1.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_alfacon-1" title="Interferon alfacon-1">Interferon alfacon-1</a></li>
<li>Interferon alpha-n3</li>
<li>Interferon beta (IFN-β) (IFNB1, <span class="new">IFNB3</span>)</li>
<li>Interferon beta 1a</li>
<li>Interferon beta 1b</li>
<li>Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)</li>
<li>Interferon omega (IFN-ω, IFNW1)</li>
<li>Peginterferon alfa-2a</li>
<li>Peginterferon alfa-2b</li></ul>

<ul><li><i>Antibodies:</i> Anifrolumab</li>
<li>Faralimomab</li>
<li><span class="new">MEDI-545</span></li>
<li>Rontalizumab</li>
<li>Sifalimumab</li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">Bifarcept</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNGR (γ, II)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interferon gamma (IFN-γ)</li>
<li><span class="new">Interferon gamma 1b</span></li></ul>

<ul><li><i>Antibodies:</i> Emapalumab</li>
<li>Fontolizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNLR (λ, III)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See IL-28R (IFNLR) here instead.</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Interleukin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TNF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK<br><small>(inhibitors)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Baricitinib</li>
<li>Filgotinib</li>
<li>Momelotinib</li>
<li>Oclacitinib</li>
<li>Ruxolitinib</li>
<li>Tofacitinib (tasocitinib, CP-690550)</li>
<li>Upadacitinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">AG-490</span></li>
<li>Atiprimod</li>
<li><span class="new">AZD-1480</span></li>
<li>Baricitinib</li>
<li><span class="new">CHZ868</span></li>
<li>Cucurbitacin I (elatericin B, JSI-124)</li>
<li>CYT387</li>
<li>Lestaurtinib</li>
<li><span class="new">NSC-7908</span></li>
<li><span class="new">NSC-33994</span></li>
<li>Pacritinib</li>
<li>Ruxolitinib</li>
<li><span class="new">SD-1008</span></li>
<li>Tofacitinib (tasocitinib, CP-690550)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">AG-490</span></li>
<li><span class="new">Cercosporamide</span></li>
<li>Decernotinib (VX-509)</li>
<li><span class="new">TCS-21311</span></li>
<li>Tofacitinib (tasocitinib, CP-690550)</li>
<li><span class="new">WHI-P 154</span></li>
<li><span class="new">ZM-39923</span></li>
<li><span class="new">ZM-449829</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional cytokines:</i> Cardiotrophin 1 (CT-1)</li>
<li>FMS-like tyrosine kinase 3 ligand (FLT3L)</li>
<li>Leukemia/leukocyte inhibitory factor (LIF)</li>
<li>Oncostatin M (OSM)</li>
<li>Thymic stromal lymphopoietin (TSLP)</li></ul>

<ul><li><i>Additional cytokine receptor modulators:</i> <span class="new">Emfilermin</span></li>
<li>Lestaurtinib</li>
<li>Midostaurin</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Growth factor receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Growth_factor_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Growth_factor_receptor_modulators" style="font-size:114%;margin:0 4em">Growth factor receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Angiopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Angiopoietin 1</li>
<li>Angiopoietin 4</li></ul>

<ul><li><i>Antagonists:</i> Angiopoietin 2</li>
<li><span class="new">Angiopoietin 3</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">CE-245677</span></li>
<li>Rebastinib</li></ul>

<ul><li><i>Antibodies:</i> Evinacumab (against angiopoietin 3)</li>
<li>Nesvacumab (against angiopoietin 2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CNTF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Axokine</li>
<li>CNTF</li>
<li><span class="new">Dapiclermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF (ErbB)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF<br><small>(ErbB1/HER1)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Amphiregulin</li>
<li>Betacellulin</li>
<li>EGF (urogastrone)</li>
<li>Epigen</li>
<li>Epiregulin</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Murodermin</li>
<li>Nepidermin</li>
<li>Transforming growth factor alpha (TGFα)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><span class="new">Agerafenib</span></li>
<li>Brigatinib</li>
<li>Canertinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Grandinin</li>
<li>Icotinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li>
<li>Osimertinib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> <a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li><span class="new">Depatuxizumab</span></li>
<li>Depatuxizumab mafodotin</li>
<li>Futuximab</li>
<li>Imgatuzumab</li>
<li>Matuzumab</li>
<li>Necitumumab</li>
<li>Nimotuzumab</li>
<li>Panitumumab</li>
<li>Zalutumumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB2/HER2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: <i>Unknown/none</i></li></ul>

<ul><li><i>Antibodies:</i> Ertumaxomab</li>
<li>Pertuzumab</li>
<li><a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a></li>
<li><span class="new">Trastuzumab duocarmazine</span></li>
<li>Trastuzumab emtansine</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Mubritinib</li>
<li>Neratinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB3/HER3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))</li></ul>

<ul><li><i>Antibodies:</i> Duligotumab</li>
<li>Patritumab</li>
<li>Seribantumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB4/HER4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Betacellulin</li>
<li>Epigen</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Neuregulins (heregulins) (1, 2, 3, 4, <span class="new">5 (tomoregulin, TMEFF)</span>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)</li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Trafermin</li>
<li><span class="new">Velafermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)</li>
<li><a href="Palifermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Palifermin" title="Palifermin">Palifermin</a></li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">Aprutumab</span></li>
<li><span class="new">Aprutumab ixadotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 8, 9, 18, 23)</li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> Burosumab (against FGF23)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 6, 8, 9, 19)</li>
<li>Trafermin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> FGF15/19</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">HGF (c-Met)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Hepatocyte growth factor</li></ul>

<ul><li><i>Potentiators:</i> Dihexa (PNB-0408)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AM7</span></li>
<li><span class="new">AMG-458</span></li>
<li><span class="new">Amuvatinib</span></li>
<li><span class="new">BMS-777607</span></li>
<li>Cabozantinib</li>
<li>Crizotinib</li>
<li>Foretinib</li>
<li><span class="new">Golvatinib</span></li>
<li><span class="new">INCB28060</span></li>
<li><span class="new">JNJ-38877605</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li><span class="new">MK-2461</span></li>
<li><span class="new">PF-04217903</span></li>
<li><span class="new">PF-2341066</span></li>
<li><span class="new">PHA-665752</span></li>
<li><span class="new">SU-11274</span></li>
<li>Tivantinib</li>
<li>Volitinib</li></ul>

<ul><li><i>Antibodies:</i> Emibetuzumab</li>
<li>Ficlatuzumab</li>
<li>Flanvotumab</li>
<li>Onartuzumab</li>
<li>Rilotumumab</li>
<li><span class="new">Telisotuzumab</span></li>
<li><span class="new">Telisotuzumab vedotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: des(1-3)IGF-1</li>
<li>Insulin-like growth factor-1 (somatomedin C)</li>
<li>IGF-1 LR3</li>
<li>Insulin-like growth factor-2 (somatomedin A)</li>
<li><a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">Insulin</a></li>
<li><a href="Mecasermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Mecasermin" title="Mecasermin">Mecasermin</a></li>
<li>Mecasermin rinfabate</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">BMS-754807</span></li>
<li>Linsitinib</li>
<li><span class="new">NVP-ADW742</span></li>
<li><span class="new">NVP-AEW541</span></li>
<li><span class="new">OSl-906</span></li></ul>

<ul><li><i>Antibodies:</i> <span class="new">AVE-1642</span></li>
<li>Cixutumumab</li>
<li>Dalotuzumab</li>
<li>Figitumumab</li>
<li>Ganitumab</li>
<li>Robatumumab</li>
<li><span class="new">R1507</span></li>
<li>Teprotumumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Insulin-like growth factor-2 (somatomedin A)</li></ul>

<ul><li><i>Antibodies:</i> Dusigitumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Binding proteins:</i> IGFBP (1, 2, 3, 4, 5, 6, 7)</li></ul>

<ul><li><i>Cleavage products/derivatives with unknown target:</i> <span class="new">Glypromate (GPE, (1-3)IGF-1)</span></li>
<li>Trofinetide</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">LNGF (p75<sup>NTR</sup>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BDNF</li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li>NGF</li>
<li>NT-3</li>
<li>NT-4</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li><span class="new">EVT-901 (SAR-127963)</span></li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Antibodies:</i> <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">LEVI-04 (p75<sup>NTR</sup>-Fc)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">PDGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Becaplermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Becaplermin" title="Becaplermin">Becaplermin</a></li>
<li>Platelet-derived growth factor (A, B, C, D)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li>Crenolanib</li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Lenvatinib</li>
<li>Masitinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Radotinib</li>
<li>Quizartinib</li>
<li>Ripretinib</li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li>Toceranib</li></ul>

<ul><li><i>Antibodies:</i> Olaratumab</li>
<li>Ramucirumab</li>
<li>Tovetumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">RET (GFL)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Glial cell line-derived neurotrophic factor (GDNF)</li>
<li><span class="new">Liatermin</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neurturin (NRTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Artemin (ARTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα4</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Persephin (PSPN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Ancestim</li>
<li>Stem cell factor</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Masitinib</li>
<li>Nilotinib</li>
<li>Pazopanib</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Trk</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkA</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li><span class="new">Gambogic amide</span></li>
<li>NGF</li>
<li>Tavilermide</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li>FX007</li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Negative allosteric modulators:</i> <span class="new">VM-902A</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">Milciclib</span></li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li>
<li>Rebastinib</li>
<li><span class="new">SNA-120 (pegylated K252a)</span>)</li></ul>

<ul><li><i>Antibodies:</i> <i>Against TrkA:</i> <span class="new">GBR-900</span>; <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">ReN-1820 (TrkAd5)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkB</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">3,7-DHF</span></li>
<li><span class="new">3,7,8,2'-THF</span></li>
<li>4'-DMA-7,8-DHF</li>
<li><span class="new">7,3'-DHF</span></li>
<li>7,8-DHF</li>
<li><span class="new">7,8,2'-THF</span></li>
<li>7,8,3'-THF</li>
<li><a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BDNF</li>
<li>BNN-20</li>
<li>Deoxygedunin</li>
<li><a href="Selegiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Deprenyl" title="Deprenyl" class="mw-redirect">Deprenyl</a></li>
<li>Diosmetin</li>
<li><span class="new">DMAQ-B1</span></li>
<li>HIOC</li>
<li>LM22A-4</li>
<li><a href="N-Acetylserotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Acetylserotonin" title="N-Acetylserotonin">N-Acetylserotonin</a></li>
<li>NT-3</li>
<li>NT-4</li>
<li>Norwogonin (5,7,8-THF)</li>
<li>R7</li>
<li>R13</li>
<li><span class="new">TDP6</span></li></ul>

<ul><li><i>Antagonists:</i> ANA-12</li>
<li>Cyclotraxin B</li>
<li>Gossypetin (3,5,7,8,3',4'-HHF)</li></ul>

<ul><li><i>Ligands:</i> <a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkC</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BNN-20</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li>NT-3</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">VEGF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Placental growth factor (PGF)</li>
<li>Ripretinib</li>
<li><span class="new">Telbermin</span></li>
<li>VEGF (A, B, C, D (FIGF))</li></ul>

<ul><li><i>Allosteric modulators:</i> Cyclotraxin B</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li><span class="new">Altiratinib</span></li>
<li>Axitinib</li>
<li>Cabozantinib</li>
<li>Cediranib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Lenvatinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Pegaptanib</li>
<li>Rebastinib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li>
<li>Tivozanib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> Alacizumab pegol</li>
<li>Bevacizumab</li>
<li>Icrucumab</li>
<li>Ramucirumab</li>
<li><a href="Ranibizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Ranibizumab" title="Ranibizumab">Ranibizumab</a></li></ul>

<ul><li><i>Decoy receptors:</i> Aflibercept</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional growth factors:</i> Adrenomedullin</li>
<li>Colony-stimulating factors (see here instead)</li>
<li>Connective tissue growth factor (CTGF)</li>
<li>Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)</li>
<li>Erythropoietin (see here instead)</li>
<li>Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)</li>
<li>Glia maturation factor (GMF)</li>
<li>Hepatoma-derived growth factor (HDGF)</li>
<li>Interleukins/T-cell growth factors (see here instead)</li>
<li>Leukemia inhibitory factor (LIF)</li>
<li>Macrophage-stimulating protein (MSP; HLP, HGFLP)</li>
<li>Midkine (NEGF2)</li>
<li>Migration-stimulating factor (MSF; PRG4)</li>
<li>Oncomodulin</li>
<li>Pituitary adenylate cyclase-activating peptide (PACAP)</li>
<li>Pleiotrophin</li>
<li>Renalase</li>
<li>Thrombopoietin (see here instead)</li>
<li>Wnt signaling proteins</li></ul>

<ul><li><i>Additional growth factor receptor modulators:</i> Cerebrolysin (neurotrophin mixture)</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Cytokine receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>











<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-06" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Sorafenib&oldid=971416142  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Sorafenib&oldid=971416142'" tppabs="https://en.wikipedia.org/wiki/?title=Sorafenib&oldid=971416142">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>